ONCN Stock Chart & Stats
$2530.00
$0.00(0.00%)
At close: 4:00 PM EDT
$2530.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2,530.00 - $2,530.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$638.83B
Enterprise Value$29.79K
Total Cash (Recent Filing)$5.10B
Total Debt (Recent Filing)$1.14B
Price to Earnings (P/E)4.7
Beta0.00
Next Earnings
Nov 05, 2026EPS Estimate
32.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)76.57
Shares Outstanding109,720,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)7.60
Price to Sales (P/S)6.20
P/FCF Ratio35.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7,125.23Price Target Upside181.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)122.38
Revenue Forecast (FY)$113.78B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 90% reflect strong pricing power and operating leverage in core oncology franchises. High gross margins provide durable cash available to fund R&D, commercial expansion and manufacturing buildouts, cushioning earnings against input cost pressures.
Strong Free Cash FlowConsistent, sizable free cash flow improves financial flexibility: it supports organic R&D, the $300M manufacturing expansion, and reduces reliance on dilutive financing. Durable cash generation strengthens balance sheet and funds late‑stage programs and commercialization.
Established Commercial LeadershipA market‑leading BTK franchise creates a durable revenue base and competitive moat: entrenched clinician adoption, large patient exposure and global footprint support predictable sales, cross‑sell opportunities and scale for new launches.
Bears Say
Elevated Leverage Vs HistoryModerate but rising leverage compared with prior years reduces financial flexibility if growth stalls or interest costs rise. Management must sustain strong cash flow and discipline on capital allocation to avoid funding pressure or constrained strategic optionality.
Growth Has CooledA deceleration to mid-single‑digit organic growth narrows the margin for error on ambitious R&D and commercial investments. Slower top‑line expansion means higher reliance on margin improvement and new product ramps to sustain EPS and cash flow trajectories.
Regulatory & Pipeline Execution RiskReliance on accelerated approvals and confirmatory trials introduces binary outcomes for product labeling and long‑term sales. Misses or slower confirmatory results (and mixed combo data like the uMRD readout) can limit revenue durability and complicate commercial planning.
BeOne Medicines News
ONCN FAQ
What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was $2530.00 and its highest was $2530.00 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $638.83B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s upcoming earnings report date is Nov 05, 2026 which is in 90 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on Aug 05, 2026. The company reported $35.269 earnings per share for the quarter, beating the consensus estimate of $28.576 by $6.692.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate is 32.84.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,720,300 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of $35.269 in its last earnings report, beating expectations of $28.576. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BeOne Medicines?
Currently, no hedge funds are holding shares in MX:ONCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7,125.23 (181.63% Upside)
$7,125.23 (181.63% Upside)
Blogger Sentiment
Bullish
MX:ONCN Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $141.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.43%
Trailing 12-Months
Company Description
BeOne Medicines
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
ONCN Company Deck
ONCN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive commercial and financial picture: robust revenue and EPS growth, raised full‑year guidance, doubled free cash flow, high gross margins, and multiple meaningful regulatory and late‑stage pipeline milestones (MANGROVE result, BEQALZI approval, BTK degrader progress). Headwinds and uncertainties were present but limited relative to the strength described — including a missed uMRD superiority in CELESTIAL‑301 (though PFS remains the primary endpoint), a $60 million tax settlement, increased operating expense guidance to fund pipeline investment, and ongoing competitive dynamics. On balance, the company emphasized durable demand for BRUKINSA, expanding global footprint, and an accelerating late‑stage pipeline, leading to an overall favorable outlook.View all MX:ONCN earnings summariesONCN Stock 12 Month Forecast
Average Price Target
$7,125.23
▲(181.63% Upside)